ARCC-4

• Target:

  PROTACs|||Androgen Receptor

• Related Pathways:

  Endocrinology/Hormones|||PROTAC

• Bioactivity:

  ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL) -recruiting AR PROTAC and outperforms enzalutamide and it is a low-nanomolar androgen receptor (AR) degrader based on PROTAC, with a DC50 of 5 nM. ARCC-4 effectively degrades clinically relevant AR mutants associated with antiandrogen therapy[1].

• Smiles:

  Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCCOc2ccc(cc2)-c2ccc(cc2)N2C(=S)N(C(=O)C2(C)C)c2ccc(C#N)c(c2)C(F)(F)F)C(C)(C)C)cc1

• Molecular Formula:

  C53H56F3N7O7S2

• Molecular Weight:

  1024.18

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  1973403-00-7